NEW YORK, NY / ACCESS Newswire / November 13, 2025 / Classover Holdings Inc. (NASDAQ:KIDZ)(NASDAQ:KIDZW) ("Classover" or the "Company"), a leading provider in K-12 educational AI, today announced its ...
Financial Assets ~~ Second Consecutive Quarter of Positive Operating Cash Flow ~~ Poised to Further Fulfill Mergers and ...
Obexelimab Phase 3 INDIGO trial topline results in Immunoglobulin G4-Related Disease (IgG4-RD) expected around year-end 2025 - - Reported highly positive 12-week primary endpoint results from Phase 2 ...
THE WOODLANDS, Texas, Nov. 12, 2025 (GLOBE NEWSWIRE) -- TWFG, Inc. ("TWFG”, the "Company” or "we”) (NASDAQ: TWFG), a ...
Lead candidate from mutant selective JAK2V617F JH2 inhibitor program advancing with IND filing expected in the first quarter of 2026Lead ...
Pipeline programs continue to advance, with four clinical data readouts anticipated in 2026; APG777 trial readout timelines accelerated, with Phase 1b in asthma and APEX 52-week Part A data in AD ...
Detailed price information for Alto Neuroscience Inc (ANRO-N) from The Globe and Mail including charting and trades.
Transformational quarter puts Envoy Medical in significantly better position as it eliminated $32 million of debt, strengthened its balance sheet, and further expanded its patent ...
Announced new clinical trial agreement with Pfizer to evaluate palazestrant in combination withatirmociclib in ER+/HER2- metastatic breast cancerInitiated OPERA-02 Phase 3 trial of palazestrant in ...
Veris Health launched commercial phase of strategic partnership and relaunched development of implantable physiological monitor PAVmed signed letter of intent ...
REVOLUTION, Invivyd’s development program for VYD2311, comprises the DECLARATION (safety and efficacy vs. placebo) and LIBERTY (exploratory safety head-to-head and combination with mRNA-based COVID ...
Coherus Oncology, Inc. (Nasdaq: CHRS), today reported financial results for the third quarter ended September 30, 2025 and provided an overview of recent business highlights. “In Q3 2025, we gained ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback